Ratings Agilent Technologies, Inc.

Equities

Market Closed - Nyse Other stock markets 04:00:02 2025-07-16 pm EDT			5-day change	1st Jan Change
113.43 ^USD	+0.43%		-6.49%	-15.56%

Jul. 15	Agilent Technologies Inc. Announces Bob McMahon to Steps Down as Senior Vice President, Effective July 31, 2025	CI
Jul. 15	Agilent Technologies Inc. Announces Chief Financial Officer Changes	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.

The firm trades with high earnings multiples: 25.05 times its 2025 earnings per share.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	AGILENT TECHNOLOGIES, INC.				32.22B
	INTUITIVE SURGICAL, INC.				184B
	THERMO FISHER SCIENTIFIC INC.				157B
	BOSTON SCIENTIFIC CORPORATION				153B
	DANAHER CORPORATION				138B
	SIEMENS HEALTHINEERS AG				60B
	EDWARDS LIFESCIENCES CORPORATION				44.66B
	RESMED, INC.				37.22B
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.				36.15B
	GE HEALTHCARE TECHNOLOGIES INC.				34.55B
	Average				87.67B
	Weighted average by Cap.